AWM
PLRX icon

Avior Wealth Management’s Pliant Therapeutics PLRX Stock Holding History

Avior Wealth Management’s Portfolio PLRX Stock Details PLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-11
Closed -$163 – 3331
2024
Q1 		$163 Buy
+11
New +$181 ﹤0.01% 2965

Other funds holding PLRX

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Avior Wealth Management's PLRX Position: Q2 2024 in Review

Avior Wealth Management sold out of Pliant Therapeutics (PLRX) in Q2 2024, closing a stake of 11 shares — an estimated $163 sold.

Avior Wealth Management first reported a position in PLRX in Q1 2024 and held it in 1 quarter. The position peaked at $163 in Q1 2024. 143 funds tracked by Wall St. Rank hold PLRX as of Q2 2024.

  • Avior Wealth Management reported no remaining Pliant Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Avior Wealth Management sold 11 Pliant Therapeutics shares in Q2 2024, an estimated $163.
  • Avior Wealth Management first reported a position in Pliant Therapeutics in Q1 2024 and held it in 1 quarter.
  • Avior Wealth Management's Pliant Therapeutics position peaked at $163 in Q1 2024.
  • 143 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q2 2024.

Based on Avior Wealth Management's 13F filing for Q2 2024, filed 13 Aug 2024.